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People with severe mental illness (SMI) have an increased risk of premature mortality, 
predominantly due to somatic health conditions. Evidence indicates that primary and tertiary 
prevention and improved treatment of somatic conditions in patients with SMI could reduce this 
excess mortality. This paper reports a protocol designed to evaluate the feasibility of a coordinated 
co-produced care program (SOFIA model, a Danish acronym for Severe Mental Illness and 
Physical Health in General Practice) in the general practice setting to reduce mortality and improve 
quality of life in patients with severe mental illness.  
 
Methods  
The SOFIA pilot trial is designed as a cluster randomized controlled trial targeting general practices 
in two regions in Denmark. We aim to include 12 practices, each of which is instructed to recruit up 
to 15 community-dwelling patients aged 18 and older with SMI. Practices will be randomized by a 
computer in a ratio of 2:1 to deliver a coordinated care program or usual care during a 6-months 
study period. A randomized algorithm is used to perform randomization. The coordinated care 
program includes educational training of general practitioners and their clinical staff educational 
training of general practitioners and their clinical staff, which covers clinical and diagnostic 
management and focus on patient-centered care of this patient group, after which general 
practitioners will provide a prolonged consultation focusing on individual needs and preferences of 
the patient with SMI and a follow-up plan if indicated. The outcomes will be parameters of the 
feasibility of the intervention and trial methods and will be assessed quantitatively and qualitatively. 
Assessments of the outcome parameters will be administered at baseline, throughout, and at end 





If necessary the intervention will be revised based on results from this study. If delivery of the 
intervention, either in its current form or after revision, is considered feasible, a future, definitive 
trial to determine the effectiveness of the intervention in reducing mortality and improving quality of 
life in patients with SMI can take place. Successful implementation of the intervention would imply 
preliminary promise for addressing health inequities in patients with SMI.  
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Trial registration 
The trial was registered in Clinical Trials as of November 5th, 2020 with registration number 
NCT04618250. URL: https://clinicaltrials.gov/ct2/show/record/NCT04618250 
 




BACKGROUND AND RATIONALE 
People with a severe mental illness (SMI) on average die younger than the general population. It is 
projected that among people with SMI, defined as psychotic conditions, bipolar disorder, and 
severe depression [1], between 10 to 20 life years are lost [2]. Unnatural causes of death, i.e. 
suicide, accidents, and homicide, considerably contribute to this disparity [3], yet chronic somatic 
health conditions account for the majority of lost life years among people with SMI [4]. The majority 
of deaths are due to cardiovascular disease, respiratory disease, and cancer [5-9]. People with 
SMI are at higher risk of several chronic somatic conditions, particularly cardiovascular diseases 
[10], diabetes mellitus type II [11], metabolic syndrome [12], respiratory diseases, and liver 
abnormalities [13] as well as the risk of somatic multimorbidity [9]. The mechanisms connecting 
SMI and somatic conditions are complex. Contributing to the higher risk of somatic conditions in 
SMI patients are unhealthy living conditions, the adverse metabolic effects of long-term 
psychotropic medication use, and possibly shared genetic and metabolic vulnerability [14, 15]. 
Finally, lower adherence to treatment regimens and poorer medical treatment are at play. 
Preliminary evidence suggests that the mortality gap for people with SMI is amenable to 
intervention and that primary care may play a pivotal role in reducing this gap [16]. 
 
People with SMI generally have a lower self-reported quality of life and have a lower 
socioeconomic status. Likewise, the label ‘mental illness has proven to have a severe negative 
social impact after being diagnosed, since all further actions and sentiments are likely to be 
understood by others in relation to, and as confirmation of, the patient’s status as mentally ill [17-
19].  
 
In the SOFIA study, an intervention was developed by combining state-of-the-art evidence-based 
clinical, and social knowledge, with the perspectives of all involved parties in a participatory co-
design process [20]. Furthermore, barriers for trans-sectoral treatment of patients with SMI, and 
potential solutions for these, were explored in a series of workshops, focus groups, and interviews 
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as part of the co-design phase to help guide the development of an intervention [21]. This 
intervention essentially aims to improve the treatment of comorbid somatic conditions in persons 
with SMI through an enhanced educational training of general practitioners and their clinical staff, 
and by implementing strategies to better accommodate patients with a psychiatric background in 
primary care. It is hypothesized that a focus on the individual patient’s needs and preferences will 
enhance the relationship between general practitioners and patients with SMI and thereby improve 
quality of life. Practically, this entails an active outreach to patients with SMI in the general practice 
setting, longer and holistic [22] consultations with attention paid to both quality of life and disease 
management, use of a conversation tool, an individualized care plan, and balancing treatment 
options against the patient’s needs, abilities, and individual circumstances. We hypothesize that 
the enhanced relationship will encourage patients with SMI in the general practice setting to attend 
health consultations systematically and regularly, which in combination with patient-centered care 
will improve timely detection and treatment of somatic morbidity. Ultimately, following this, we 
hypothesize that this intervention will reduce excess mortality and enhance the needs-based 
quality of life in patients with SMI.   
 
In short, the intervention includes prolonged clinical consultations with full reimbursement, a full-
day introductory educational course for general practitioners and practice staff, and the distribution 
of a handbook promoting trans-sectional care. Components of the design and intervention, similar 
to those from the SOFIA intervention, have been used and assessed in previous trials [23, 24]. 
However, none of these interventions were specifically aimed at patients with severe psychiatric 
morbidity in the general practice setting. Furthermore, few studies have looked into how general 
practice can improve the lives of people with multimorbidity or have investigated the efficacy of 
training doctors to manage people with multimorbidity [25]. Therefore, in light of this paucity of 
evidence regarding management of care in this patient group in the general practice setting, 
conducting an RCT raises significant practical concerns. Moreover, when developing a complex 
intervention, a scaled approach is recommended, i.e. from small-scale feasibility studies to larger-
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scale pilot trials before an RCT can take place to ensure that the intervention is sequentially 
optimized, is implementable, cost-effective, and acceptable to patients and providers [26]. 
 
Before this pilot study, we conducted a small-scale single-arm feasibility study, which 
demonstrated that the recruitment to and completion of the prolonged consultation was feasible in 
general practice (unpublished raw data). However, we identified several challenges regarding the 
optimal method for recruitment of patients, ensuring implementation of the intervention in practice, 
optimizing the data collection process, and the quality of data. Also, the educational component of 
the intervention was not tested in the small-scale single-arm feasibility study, and neither was the 
impact of randomization on patients’ willingness to participate and on practices' behavior. 
Therefore, we will undertake a cluster randomized pilot trial before assessing the efficacy of the 
SOFIA intervention in a larger-scale RCT. We considered usual care as an appropriate comparator 
as it likely approaches the naturalistic conditions for patients with SMI in the general practice 
setting. 
 
The primary objectives of this pilot study are:  
 
1. To assess the implementability of the intervention including the fidelity and acceptability of the 
intervention for patients and general practitioners; 
2. To assess the feasibility of the design in terms of recruitment of practices and patients; and to 
assess retention of patients and practices during the intervention; 
3. To assess the feasibility of collection of outcome measures; and. thereby obtain preliminary data 
to inform the required sample size in a definitive, large-scale efficacy trial- hereafter referred to as 
”The SOFIA Trial”. 
The secondary objectives of the study are: 




2. To examine to which extent general practitioners’ use of patients’ response to the MultiMorbidity 
Questionnaire (MMQ) (see section Data collection before randomization for a description of the 
MMQ below), measuring quality of life in patients with multimorbidity, during the prolonged 
consultations threatens the validity of the questionnaire as an outcome measure; 
3. To assess and inform selected aspects of the program theory relating to the prolonged 




The pilot study is designed as a randomized, non-blinded, parallel-group trial. A 2:1 cluster 
randomization will be performed with the general practice level as the unit of randomization.  
 
Trial setting  
The study will be conducted in the Capital Region of Denmark (excluding the island Bornholm) and 
the Region of Zealand. Region Zealand includes the island Zealand, which it shares with the 
Capital Region, and the adjacent islands, Lolland, Falster, and Møn. In these two regions, 
approximately 1600-1800 patients are enlisted per general practitioner.  
 
Eligibility criteria  
In- and exclusion criteria of general practices 
General practices have to be located in the Capital Region of Denmark and the Region of Zealand. 
General practices without permanent staff, so-called regional clinics or clinics run by private firms, 
are not included due to lack of continuity of care, which is assumed to be a critical underlying 
component of the hypothesized effect of the intervention. General practices that have participated 
recently or still participate in trials similar to the SOFIA trial will be excluded. No other in- or 




Recruitment of general practices 
General practices will be invited to participate by the research team. More than one general 
practitioner may be employed at a single practice. To participate in the trial, all general 
practitioners employed at a practice should agree to participate. We aim to recruit 6 general 
practices in the Capital Region and 6 general practices in Region Zealand. Each Region is divided 
into multiple municipalities. We aim to recruit practices from different municipalities to increase the 
generalisability of the pilot study to inform the feasibility of a larger-scale RCT. Practices are 
recruited via telephone, followed by an email with information about the study and a further 
telephone call in which practices confirm or decline participation. General practices confirming 
interest in participating in the study will be visited by members of the research team. During this 
visit, practices will be provided instructions and materials for recruitment of patients, data 
collection, and any other information needed to conduct the trial.  
 
Inclusion criteria primary care patients with SMI  
Patients will be included if they: 




B1. Have a psychotic disorder  
[-Registered at general practice with International Classification of Primary Care version 2 (ICPC-2) 
psychiatric diagnosis p72 (psychotic disorders) which roughly corresponds to International 




B2. Have a bipolar disorder 
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[-Registered at general practice with ICPC-2 diagnosis of p73, bipolar mood disorders, roughly 
corresponding to ICD-10 codes F30-F31, and F34.0; Or have a prescription of lithium (Anatomical 
Therapeutic Chemical classification (ATC) N05AN); Or are registered at general practice with 
ICPC-2 diagnosis p76, unipolar depressive disorders, roughly corresponding to ICD-10 codes 
F32.2 - F32.3, and/or F33.2- F33.3, and F53.0; And have a prescription of Lamotrigine (N03AX09) 




B3. Have a severe depressive disorder.  
[-Registered at general practice with ICPC-2 diagnosis p76, unipolar depressive disorders roughly 
corresponding to ICD-10 codes F32.2 - F32.3, and/or F33.2- F33.3, and F53.0; And have a 
prescription of tricyclic antidepressants (ATC: N06AA) and/or Selective Norepinephrine Receptor 
Inhibitors (SNRI) venlafaxine (N06AX16) and duloxetine (N06AX21) and/or Monoamine Oxidase A 
Inhibitor (MAOI) (N06AG) and/or non-selective MAOI (N06AF).] 
 
Exclusion criteria primary care patients with SMI 
Patients will be excluded from participation if they are: 
A. Subjected to any type of legal measure as stipulated in the Danish Mental Health Care Act 
(Psykiatriloven), e.g. forced detention or medication;  
B. Registered with a dementia diagnosis ICPC-2 p70, roughly corresponding to ICD-10 F0.01-0.03 
or registered with organic psychosyndrome or other neurological diseases (ICPC-2 P71, N73, 
N99); 
C. Receiving end-of-life care; 
D. Non-Danish speakers;  
E. Psychiatric diagnosis appears to be incorrect or outdated;  
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F. Assumed by the patient’s general practitioner to have an overall functional level that is too low 
for meaningful participation in the trial (use of this criterion will be evaluated on an individual basis 
by the trial management team to minimize the risk of selective inclusion). 
 
Identification, eligibility assessment, and recruitment of patients with SMI  
Participating practices will be instructed to collect the International Classification of Primary Care 
version 2 (ICPC-2) codes and ATC-codes from the electronic medical record on all patients who 
are registered at the practice at the commencement of the study and send these to the research 
team. ICPC-2 codes are routinely used in Danish medical practice. 
 
A computer algorithm will randomly select a sample of 45 patients who fulfill the externally 
verifiable inclusion criteria for each participating general practice. This selection will be stratified, in 
that each sample of 45 patients includes 15 patients who meet diagnostic criteria B1, B2, or B3 
respectively. The research team sends this list of 45 potentially eligible patients to the general 
practitioners. General practitioners are instructed to screen these lists for correct diagnoses. In 
case of uncertainty regarding diagnosis, general practitioners should contact the research team. 
When a diagnosis is verified by the general practitioner, the general practitioner will assess the 
eligibility of the listed patients according to the exclusion criteria described above. General 
practitioners are instructed to document any reasons for exclusions and any reasons for deviating 
from the exclusion criteria. General practitioners are instructed to recruit at least 2 patients from 
each diagnostic subgroup (corresponding to the inclusion criteria B1, B2, and B3). We employ a 
reimbursement limit of 15 patients per practice. Patients participating in the study will not receive 
financial compensation. 
 
The general practices will establish the initial contact with patients who were found eligible. 
Practice staff will contact potentially eligible patients via telephone, and provide brief oral 
information about the study. When approaching patients, practice personnel are instructed to 
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register the date and means of contact, e.g. telephone or email, and the number of attempts. In 
case the patient does not respond, an email, text message, or message on voicemail is sent. If a 
patient cannot be reached after at least three attempts, the patient will be excluded from 
participation.  Patients, who express interest in participating in the study, will be invited to an initial 
10-30-minute enrolment visit at the general practice. General practices are instructed by the 
research team to send an information leaflet and a copy of the informed consent form by mail or 
email to patients before they visit their practice. During the enrolment visit, further questions 
regarding the study will be discussed. If patients agree to participate, written informed consent will 
be obtained. Moreover, all patients receive the questionnaires MMQ and the EQ-5D-5L measuring 
quality of life and health status after they visited their practice. Patients can either choose to 
receive the questionnaire in print from their general practice or via their e-Boks (provider of secure 
platforms and digital post-boxes) from the research team. A more detailed description of the 
properties of these questionnaires is provided below in the paragraph Data collection before 
randomization - quality of life measurements. Patients are asked by the general practitioner to 
complete these questionnaires online through a link in their secured email or return them by mail in 
a prepaid envelop to the research team.  
 
Interventions 
Intervention group  
Prolonged clinical consultations: The SOFIA consultation  
Patients, whose general practice has been allocated to the intervention arm, will be invited to a 
prolonged consultation after the general practitioners have attended an introductory educational 
course (see below). All patients will be encouraged to bring a relative or social worker if applicable. 
Non-attenders will be contacted to reschedule missed appointments.  
 
The prolonged consultation will be held by the general practitioner and will follow the SOFIA 
scheme, which is a further development of the existing consultation practice and communication 
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skills as taught during Danish general practitioners’ specialty training [27]. In the consultation, 
SOFIA stands for SOcial, FInding, and Agreement, which guides the flow of the SOFIA 
consultation. The structure of the prolonged consultation is described in Box 1. The consultation 
will primarily focus on somatic health problems. The consultations will last up to 45 minutes, which 
includes time for preparation, ordering paraclinical testing, and referrals. Paraclinical tests and 
other indicated point-of-care tests will be performed by practice staff.  
 
Introductory educational course 
A mandatory one-day course for all general practices assigned to the intervention group will be 
held. The course aims to provide additional education on challenges and pitfalls when delivering 
care for patients with SMI and to instruct general practitioners on how to conduct the SOFIA 
consultation. An academic general practitioner will provide hands-on tools for the clinical and 
diagnostic management of this patient group. Then a workshop will be conducted on how to 
include patients with SMI’s individual social and cultural aspects during the consultation and in the 
planning of treatments, including how to tackle ie substance abuse. The training will also include 
how to do a medication review, taught by a pharmacologist, and practical information about 
participating in the study. Finally, a patient will be providing the patient perspective of being treated 
for somatic diseases while also suffering from SMI. This will add to the training's final hands-on 
sessions on conducting the SOFIA consultation. The training is built upon the pedagogical 
principles of transfer [28] and will be followed up by a pre-organized peer-to-peer session and 
continuous support from the project office. The training will be assessed in a feasibility study in 
which fidelity and acceptability will provide a deeper insight into how the training is transferred and 
maintained in a clinical everyday setting, rather than solely evaluating the participants’ satisfaction 






Promoting trans-sectional care – the SOFIA handbook 
Owing to the Danish organization of health care and social care into different sectors resorting 
under separate laws, formal trans-sectional care plans are not feasible. However, each general 
practitioner assigned to the intervention arm will receive a specialized handbook, specific for their 
municipality and regional affiliation, containing contact information of relevant social or health care 
actors, and helplines in case of substance abuse and an increased risk of suicide and self-harm. 
 
MMQ part 1 
Apart from improving physical health, the SOFIA study aims to improve the quality of life among 
the participants. To measure the quality of life, we use the patient-related outcome measure, MMQ. 
MMQ was developed for patients with multimorbidity, including SMI. In the SOFIA pilot trial, we 
want to examine if the simultaneous use of MMQ as a conversation tool and an outcome 
assessment, will bias the MMQ as an outcome measure. Therefore, the general practices will be 
cluster-randomized in two subgroups, with 2 general practices from each region in both subgroups. 
All patients are asked to complete the MMQ part 1 (MMQ1) before the prolonged consultation. In 
the first subgroup, the relative sum-scores of six scales will be provided to the general practitioners 
via an electronic link. During the educational course, the general practitioners in the first subgroup 
are instructed on how to use the six scales’ sum-scores as a clinical conversation aid during the 
‘patient part’ of the consultation. In the other subgroup, the general practitioners will not have 
access to the MMQ1 scores.  
 
Control group 
Primary care patients in the control group will receive usual care during the study period. In the 
control group, the general practitioners will not have access to the MMQ1 six scales’ sum scores. 
Usual care includes free access to primary healthcare both during and out of office hours.  Of 
relevance in this context is that in Denmark all primary care patients suffering from chronic 
conditions, i.e. diabetes, cardiovascular diseases, COPD and asthma, rheumatoid arthritis, 
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osteoporosis, thyroid conditions, and all mental conditions, are offered an annual disorder-specific 
health-check, and medication and treatment review by their general practitioner.   
 
End-of study 
The study period ends September 30th, 2021. All patients in the intervention and control group 
receive the same questionnaires as at baseline (MMQ, EQ-5D-5L) to be returned to the research 
team by mail or through RedCap. This concludes the study period for all participating patients. 
 
Concomitant care 
Any new interventions or initiatives introduced by local health authorities, municipalities, 
researchers, health organizations, and the like, aimed at improving healthcare for persons with 
psychiatric conditions, will be recorded during the study. 
 
Outcomes measures 
The overall aim of the pilot trial is to assess the feasibility and quality of trial management, 
intervention content, and implementation. To qualify the content of the intervention and its 
implementation, a formative process evaluation of the pilot trial will be conducted with a twofold 
purpose: to assess the implementation platform and to inform the definitive SOFIA trials’ preliminary 
program theory [29]. The formative aspect of the evaluation will ensure more rapid feedback which 
can give rise to iterative changes during the pilot trial after which the results of these adjustments 
can be assessed. This formative approach will maximize the potential for an optimum model before 
the definitive trial [29]. The study design is a mixed-method study using data from an electronic data 
registration system (REDCap, see below), registers, and qualitative methods (interviews and 
observations). For the objectives, where threshold criteria are given, these will be used to decide if, 
and in that case, how to progress to the large-scale RCT. Not reaching these thresholds doesn’t 
necessarily indicate unfeasibility but will be an incentive to re-evaluate and possibly adjust the design 




Primary outcome measures 
1. To assess the implementability of the intervention  
Concerning the implementation, we will assess the implementation platform for the intervention by 
assessing fidelity (if and to what extent the intervention was performed as planned and the 
educational recommendations were followed) and barriers and facilitators for implementation 
concerning e.g., comprehensibility, acceptability by practices, preparation, and the integration of the 
intervention into existing practices. This will be done by performing qualitative semi-structured 
interviews with general practitioners and staff in the intervention group during the pilot trial and 
observations of the introductory course and prolonged consultations.  
 
2. To assess the feasibility of the design in terms of recruitment of practices and patients 
and assess retention of patients during the intervention 
The feasibility of the recruitment of practices and patients will be assessed using the proportion of 
contacted general practices, which agree to participate in the study and the eligibility and consent 
rate of patients. We consider a participation rate of at least 20% of the contacted general practices 
and at least 60% of the contacted patients as an indication that our recruitment strategy is feasible. 
Based on registrations by the practices in REDCap, feedback and questions regarding support 
from practices during the process, and interviews with general practitioners and staff after the 
recruitment process, we will assess the appropriateness of the recruitment process and the 
introduction and support to the participating practices.  
Retention of patients will be assessed as the proportion of recruited patients in the intervention 
group who attend the first consultation, and the minimum threshold for attendance is set at 90%. 
Information on measures such as non-return of consent forms, non-shows by participating patients 
in general practice, difficulties reaching patients will be collected. Based on interviews with the 





3. To assess the feasibility of collection of outcome measures and thereby obtain 
preliminary data to inform the required sample size in the definitive trial  
All patients, regardless of allocation, will complete the two outcome questionnaires the MMQ and 
the EQ-5D-5L questionnaire at baseline, after randomization, and at the end of the pilot trial.  
Based on the number of returned questionnaires, we will calculate response rates and the 
proportion of missing data in each completed questionnaire. We set a minimum acceptable 
threshold for the response rate before randomization of both questionnaires at >90% with a 
maximum proportion of missing data at <10%. We set a minimally acceptable response rate at 
>90% for both questionnaires at the end of the study period in both the intervention and the control 
group.  
 
Data on mortality and in- and outpatient admissions during the study period in the participating 
patients will be collected from the national patient registries after completion of the pilot trial. These 
data, along with the scores of the MMQ, and the EQ-5D-5L questionnaires, will be used to estimate 
the necessary sample size to power the definitive trial, which primary endpoints are mortality and 
quality of life, as measured by the MMQ. 
 
 
Secondary outcome measures 
1. To examine whether our recruitment strategy is at risk for preferential inclusion of 
patients with a favorable prognosis 
To assess if, and to what extent, selective recruitment is present in our study, we aim to use 
national patient registries and registrations in REDCap to examine potential differences in 
demographic, socio-economic, and health-related characteristics between eligible patients who 




2. To examine to which extent use of the quality of life questionnaire (MMQ1) during the 
prolonged consultations threatens the validity of the questionnaire as an outcome measure 
It is the intention, in the definitive trial, that the general practitioners can use the MMQ1 as a 
conversation tool to help them identify issues that should be addressed during the consultation. In 
this scenario, in the intervention arm, the general practitioners have access to the aggregated 
patients’ MMQ scores, and patients might have a different understanding of the questions after 
having discussed them during the consultation as opposed to the participants in the control group. 
This might compromise the validity of the MMQ1 as a primary outcome in the definitive trial. Within 
the pilot study, we aim to empirically test for this risk of bias. To this end, in randomly selected 50% 
of the intervention practices, the general practitioner will have access to the aggregated score of 
selected domains in the MMQ1. In the remaining 50% of the intervention practices, MMQ1 scores 
will be concealed for the general practitioner. This sub-study is designed as a small equivalence 
trial nested in the pilot study. The aim is to show that the two approaches are not different in terms 
of mean change in MMQ1 scores before and after the intervention by using the scores of MMQ2 
and EQ-5D-5L as anchors. 
 
3. To assess and inform selected aspects of program theory relating to the prolonged 
consultations and the educational course 
Concerning the program theory, we will assess selected proposed connections, mechanisms, and 
contextual conditions influencing intervention implementation and outcomes. Mainly to gain a 
preliminary indication of the effectiveness of the prolonged consultations (change in diagnosis, 
medication, referrals, increased contact) and the effectiveness of the educational course in changing 
the clinical practice approach. This can give rise to elaborations of the program theory and 
adjustments of the intervention before the definitive trial. These issues will be assessed by a 
combination of the registrations in REDCap, observations, and interviews with practices in the 
intervention group. Furthermore, we will conduct interviews in all allocation groups on usual care and 





An overview of the schedule of enrolment, interventions, assessments, and visits for participants is 
given in Table 1. 
 
Power analysis and sample size 
As this is a pilot trial, a formal sample size calculation is not performed. We aim to include 12 
practices, each recruiting up to 15 patients per practice, amounting up to 180 patients in total. We 
considered this number sufficiently informative on the practicalities of delivering the intervention 
and collecting outcome data.   
 
Allocation and concealment 
Unit of randomization will be the general practice so that all participating patients within the general 
practice receive either the intervention or care-as-usual. General practices will be randomly 
assigned on a 2:1 basis to either the intervention or care-as-usual group in blocks of three within 
each region. A block of three practices will be allocated simultaneously after completion of the 
baseline documentation for all study participants within the practices. Within each randomization 
block of 3 practices, we further randomize 1 of the 2 practices in the intervention arm to a sub-
group, where the general practitioner has access to the aggregated scores of the MMQ1. The 
other intervention practice within the randomization block of 3, will be allocated to a sub-group in 
which MMQ1 scores will be concealed for the general practitioner. A computer randomized 
allocation sequence will be concealed until all general practices are assigned. Patients will be 
informed that they are allocated to the intervention arm or the control group by the research team 
through e-Boks. 
 
Blinding (masking)  
All researchers working on quantitative analyses will be blinded to practice allocation. It is not 
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possible to blind qualitative researchers as they analyze data, they have collected themselves.  
Due to the nature of the intervention, it will not be possible to blind the participants or other 
members of the research team to allocation.  
 
Data collection before randomization 
1. General practice data 
Data collected about the general practices will include service number of the general practice 
(Danish: ydernummer), address, name(s) of general practitioners, number of patients registered at 
the practice, number of staff (including nursing staff and administrative staff). 
 
2. Patient demographics and medical history 
The following information will be recorded in REDCap by practice staff: CPR-number (Danish 
social security number), sex, age, ICPC-2 codes, and ICD-10 diagnostic codes. Reasons for non-
eligibility will be recorded. 
 
3. Quality of life measurements 
For all recruited participants the MMQ and EQ-5D-5L will be collected before allocation.  
 
MMQ 
The validated version of the MultiMorbidity Questionnaire (MMQ) encompasses two parts: MMQ1 
and MMQ2. MMQ1 measures needs-based quality of life and MMQ2 measures self-perceived 
social inequity. MMQ1 encompasses 6 scales measuring: Physical ability (6 items); Worries (6 
items); Limitations in everyday life (10 items); My social life (6 items), Self-Image (6 items); and 
Personal economy (3 items). The development of the items and the scales is based on the Needs-
based model for quality of life. MMQ2 encompasses different numbers of scales, with different 
numbers of items, that measure different constructs of self-perceived social inequity addressed 
towards five different types of contacts: General practitioners, the clinical staff at the general 
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The EQ-5D-5L is a standardized measure of health status developed by the EuroQol Group to 
provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L 
descriptive system comprises the five dimensions: mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression. Each dimension has five response levels: no problems, 
slight problems, moderate problems, severe problems, unable to/extreme problems. The 
respondent should indicate his/her health state by checking the box next to the most appropriate 
response level for each of the five dimensions [30].  
 
Data collection during the study period  
1. Data from practices’ electronic medical records 
From the practices’ electronic medical records data will be recorded in REDCap by practice staff 
on patient characteristics, recruitment rates, response rates of consent forms, attendance rates of 
patients in the intervention group.  The SOFIA study’s trial research team provides support to 
practices and can monitor progress in each practice via REDCap in real-time.  
 
2. Qualitative data on trial management, implementation and program theory 
Semi-structured interviews with general practitioners and, staff will be conducted concerning the 
recruitment process, the educational course, the preparation and execution of the prolonged 
consultations, and at the end of the study. Observations will be performed of the information 






End-of-study data collection 
1. Mortality and morbidity data 
Data on mortality and in- and outpatient hospital admissions during the study period in the 
participating patients will be collected from the National Patient Registries after completion of the 
pilot trial. 
 
2. Response rates and quality of life measurements 
For all recruited participants, the MMQ and the EQ-5D-5L will be collected at end of the study 
period. Questionnaires will be either sent through REDCap to their e-Boks or by regular mail or 
email to participants in the intervention and control group at the end of the study period. 
 
3. Medication 
Data on the type of redeemed medication prescriptions from the 12 months before randomization 
and during the study period, will be collected from the Danish national health service prescription 
database.  
 
4. Biochemical and biometric data  
Biochemical and biometric data available for the 12-month period before randomization, the study 
period, and up to 6 months after the study period will be collected concerning participants allocated 
to the intervention and control group. Electrocardiogram (EKG), serum hemoglobin A1C (HbA1c) 
serum HDL, LDL, and total cholesterol will be collected from a centralized clinical chemical laboratory 
database. Height, weight, and systolic and diastolic blood pressure values will be collected by the 
practice staff or the general practitioner from the electronic medical record and recorded in REDCap.  
 
Data management 
The study will commence upon approval by the relevant Danish authorities and strictly adhere to 
Danish law governing medical research in humans and safeguarding of personal information of any 
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kind. Data is stored and handled according to the General Data Protection Regulation. The study 
owner is responsible that all study activities comply with the Danish law on handling of personal data. 
The study owner is responsible that the identities of the participants are kept strictly confidential. To 
ensure these objectives, information that might allow identification of participants (e.g. name, CPR 
number, contact information) will also be encrypted and located on secure password-protected 
servers where all activity is subjected to transaction logging. All data that might allow identification 




The quantitative parts of the primary objectives in this pilot study, e.g. the rate of recruitment of 
general practitioners and patients, retention of patients, outcome data, will primarily contain 
descriptive statistics to assess the quality of these parameters: Mean (standard deviation) for 
continuously measured objectives, and raw count (%) for categorically measured objectives. For 
some objectives, the difference between the randomization groups is of interest, and this will be 
assessed statistically in linear or logistic regression models.   
 
Qualitative methods 
Interviews will be recorded and transcribed, and notes will be taken systematically during 
observations. All qualitative data will be analyzed with qualitative methods ensuring a systematic 
and transparent approach and several researchers will cooperate and reach a consensus of the 
coding structure and analysis of the data. The software program NVivo will be used in the process 







Data monitoring  
Due to the short duration of the trial and minimal health risks for the participating practices and 




The study aims to improve the overall health and quality of life for a group of Danish citizens that are 
currently not receiving the indicated treatment for common conditions, and who experience the 
highest level of inequality and inequity in healthcare. The value of the study lies in its ability to identify 
and treat or support people with multiple conditions and to provide them with the appropriate clinical 
care to reduce the risk of premature death from untreated or undertreated somatic conditions.  
 
A potentially harmful effect of our study is overdiagnosis. Since the study aims to identify and treat 
undiagnosed conditions, certain deviations, abnormalities, risk factors, or pathologies may be 
detected that were never going to cause harm. The limited sample size of the pilot trial prevents 
appropriate analyses of any potential harms and will therefore not be performed. 
 
We expect that neither acceptance nor rejection from patients to participate in the study will affect 
the quality of clinical treatment by their general practitioner. The general practitioners that are 
allocated to the intervention arm will have received training in working with patients with SMI. Hence, 
it is anticipated that the care for the patients that do not wish to participate is better relative to the 
treatment they would have received otherwise.  
 
Modifications of protocol 
Any modifications to the protocol that may affect the conduct of the study, the potential benefit of 
the patient or may affect patient safety, including changes of study objectives, study design, patient 
population, sample sizes, study procedures, or significant administrative aspects will require a 
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formal amendment to the protocol. Such amendments will be agreed upon by the steering 
committee and the primary funder and should be approved by the Ethics Committee before 
implementation.  
 
Administrative changes to the protocol are minor corrections and/or clarifications that do not affect 
the way the study is to be conducted. These administrative changes will be agreed upon by the 
steering committee and the primary funder and will be documented in a memorandum.  
 
Consent 
An initial enrolment visit at the general practices is offered to individuals responding positively to 
the initial invitation to participate. The initial enrolment visit is scheduled at the convenience of the 
respondent. The visit will be held in a standard consultation room safeguarded against 
interruptions, including telephones or other disturbing elements. The visit is held by a member of 
the clinical staff employed by the general practitioner. Information material about the trial and a 
copy of the consent form is sent to the potential participant before the appointment. At the initial 
enrolment visit, clinical staff provides key information about the trial and answers any questions. 
Instructions guiding the initial enrolment visit are made to ensure that adequate care is taken to 
present all essential background, practical details as well as ethical considerations and that this 
information is understood by the patient.  
 
Confidentiality 
All study-related information will be stored securely and electronically in REDCap, which complies 
with the demands set forth by the General Data Protection Regulation. This includes forms, lists, 
logbooks, appointment books, and any other listings that link participant ID numbers to other 
identifying information. All reports, data collection, process, and administrative forms will be 
identified by an identification number only to maintain participant confidentiality. All records that 
contain names or other personal identifiers, such as locator forms and informed consent forms, will 
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be stored separately from study records identified by a code number on a secure server. All local 
databases will be secured with password-protected access systems. Participants’ study 
information will not be released outside of the study without the written permission of the 
participant. 
 
Access to data 
The trial manager will grant access to quantitative data sets following individual assessment to 
ensure that members of the research team only have access to data that they need. Study data sets 
will be housed on REDCap and Secure Information Facility (SIF), a secure server hosted by the 
University of Copenhagen. To ensure confidentiality, data dispersed to research team members will 
be devoid of any identifying participant information. The qualitative data will be stored as detailed 
above in pseudonymized form and analyzed in anonymous form in the software NVivo by relevant 
researchers. The research group will guide the operational management of the trial, with 
responsibility for the overall supervision of the study.  
 
Dissemination policy 
All results from the study (be it positive, negative, or inconclusive) will be published in peer-
reviewed journals. The final list and order of authors follow the contribution from each researcher 
and follows the Vancouver rules and the guidelines from The Danish Committees on Scientific 
Dishonesty. In case the list and order of co-authors cannot be decided jointly by researchers, this 
decision will be made by the study owner. In case of disagreement on the validity, presentation, or 
interpretation of the results each researcher is free to publish independently as outlined by the 








The date of pilot trial protocol registration was 05/11/2020, and the registration number is 
NCT04618250. Recruitment of general practitioners started on November 6th, 2020, and was 
approximately completed on March 15th,2021. 
 
DISCUSSION 
The overarching goal of this cluster-randomized pilot trial is to determine the feasibility and 
acceptability of conducting a definitive randomized control trial to evaluate a coordinated co-
produced care program in the general practice setting to reduce mortality and improve quality of 
life in patients with a severe mental illness. If delivery of the intervention proves feasible, a 
definitive trial to determine the effectiveness of the intervention can take place.  
 
Our recruitment strategy might be biased towards patients who are already willing to receive and 
seek medical attention. Preferential recruitment of these patients will limit the generalizability of our 
findings and may reduce the observed efficacy of our intervention in a future definitive trial. 
Preferential selection of trial participants with favorable prognostic characteristics is widely 
acknowledged, yet typically ignored in trials [31]. In our pilot study, we, therefore, examine the risk 
of selective recruitment. If the risk of selective recruitment is present, we will re-evaluate and, if 
needed, adjust the recruitment strategy. Another limitation of the study design involves the 
randomization at the level of the general practice rather than at the individual patient. In the 
definitive trial, outcomes will be measured at the individual patient level, yet the intervention is 
targeted at the general practitioner and the practice staff. As staff and general practitioners will not 
be able to adapt care provision on an individual basis depending on allocation, randomization at 
the patient level will inevitably introduce contamination bias and lead to underestimation of the 
potential effectiveness of the intervention. However, randomization at a cluster level might 
challenge the comparability of the intervention and the control group [32]. Analysis of the definitive 
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RCT will therefore require correction for potential imbalances in patient and practice 
characteristics. 
 
The COVID-19 pandemic will likely influence the course and outcome of this pilot study. Until 
widespread immunization against COVID-19 is in place, resurgences of the pandemic will 
occasionally restrict access to primary health care for patients [33]. This will exacerbate the pre-
existing barriers people with severe mental illness encounter when seeking medical attention, 
emphasizing the timeliness of research of feasibility, acceptability, and ultimately efficacy of 
interventions aimed to improve access to health care for this vulnerable patient group [34].  
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Box 1: The SOFIA scheme 
Welcome  
Patient and general practitioner agree on the aim of consultation. Information about the study 
and participation is repeated. It is orally confirmed that informed consent for study participation 
has been given.   
SOcial clinical space: The “patient part” of the consultation 
This opening part of the consultation aims to establish a positive relationship between the patient 
and the general practitioner. The patient has the opportunity to present his or her complaints and 
through clarifying the patient’s thoughts, feelings, and notions regarding these complaints. The 
general practitioner sets an agenda for the consultations. Suggestions for open questions the 
general practitioner could ask are:   
 
“How are you? Is there anything that you would like to focus on today? Are there any other 
concerns that I should be aware of? Is there anything in particular that you hope to gain from 
today’s meeting and is there anything that you hope that I can help you with?”  
 
Dependent on the study arm the patient is allocated to, results from MMQ1 may be discussed. 
The general practitioner is instructed to probe for areas that need attention and needs that 
should be focused on, especially if the patient’s sum score in any of the six scales indicates poor 
quality of life in the construct measured by the scale. The general practitioners are instructed to 
ask, whether the patient experiences suicidal thoughts (if so general practitioners are instructed 
to follow the SOFIA handbooks’ guide on talking about suicide). If not already known, general 
practitioners ask about possible substance abuse, self-harm (if yes, see the SOFIA handbook for 
referrals).  
 
FInd any symptoms for undiagnosed or undertreated somatic diseases: The “general 
practitioners’ part” of the consultation 
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The middle section of the consultation aims to collect information on current diagnoses and their 
treatments and to detect possible, unrecognized, and undertreated disorders or overdiagnosed 
and/or overtreated conditions. The general practitioners are instructed to ask about known 
diseases and current treatments and any symptoms that the patient may experience. The 
general practitioners will perform a focused physical somatic diagnostic interview, based on any 
somatic concerns that the patient and general practitioner agree upon. The patient must be 
physically examined, even if the patients have no physical complaints, because of the delayed 
and altered bodily experience often accompanying SMI. The general practitioners conclude this 
part of the consultation with a brief review of current medication and, if relevant, make a plan to 
optimize pharmacological treatment. The general practitioners discuss adherence challenges 
related to treatment, possible side effects, and any possible considerations or wishes for 
medication changes with the patient. If required, a pharmacologist can be consulted by email. If 
required, a follow-up consultation focusing on medications will be scheduled. 
 
Agree on individual care plan (final step of the SOFIA consultation) 
During the final part of the consultations, an individual care plan is made. The general 
practitioner and the patient will discuss current treatment with the patient, i.e. is the patient 
adequately treated for his/her current conditions. The general practitioner and patient assess 
whether treatment adjustments are needed. The general practitioner explores if anything 
discussed during the consultation requires follow-up, i.e. referrals to municipality or psychologist, 
or referral to “institutional care facility” or other services as provided by the SOFIA handbook. 
The general practitioner creates a safety-net – by emphasizing that the patient is always 
welcome to contact the practice. If medically indicated, paraclinical tests and follow-up 






Table 1: participants’ timeline 
 STUDY PERIOD 
 Enrolment Allocation Post-allocation Close-out 
TIMEPOINT  -5 months 0 >0-6 months >6 months 
ENROLMENT:     
Recruitment general 
practices 
X    
Identification patients X    
Eligibility screen 
patients 
X    
Informed consent X    
Allocation  X   
INTERVENTIONS:     
Educational course 
general practitioners 
  X  
Prolonged 
consultations 
  X  
ASSESSMENTS:     
Patient demographics X    
MMQ1 X X  X 
MMQ2 X X  X 
EQ5D-5L X   X 
Data on retention 
patients  
   X 
Mortality data    X 
Socioeconomic status    X 
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Paraclinical test data    X 
Medication use     X 
Hospital admission 
data 
   X 
Ethnographic 
Interviews 
X X X X 
 
